BioSpace News Archive

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 5, 2021 to report its first quarter 2021 financial results and discuss recent corporate developments.

Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Wednesday, May 5, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2021.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the initiation of PRESERVE 2, a pivotal Phase 3, randomized, double-blind, placebo-controlled study of COSELA™ (trilaciclib) in patients receiving first- or second-line gemcitabine and carboplatin chemotherapy for locally advanced unresectable or metastatic triple-negative breast cancer (mTNBC).

In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression.

Global Blood Therapeutics, Inc. announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close.

ADMA Increases Total Forecasted Plant Manufacturing Capacity from 400,000 Liters up to 600,000 Liters and Increases Total Forecasted Peak Revenues in Excess of $300 Million

Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology 2021 Annual Meeting taking place virtually June 4-8, 2021.

FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 5:00 PM Eastern Time.

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27.